# Survodutide > Investigational glucagon / GLP-1 dual agonist from Boehringer Ingelheim — Phase 3 for obesity and MASH. - Also known as: BI 456906 - Class: Metabolic - FDA approved: No - Canonical page: https://americanpeptide.com/catalog/survodutide ## Overview Survodutide (BI 456906) is an investigational once-weekly peptide that activates both the glucagon and GLP-1 receptors. Adding glucagon-receptor agonism to GLP-1 is studied as a way to raise energy expenditure and target liver fat on top of GLP-1’s appetite and glycemic effects. Developed by Boehringer Ingelheim with Zealand Pharma, it is in Phase 3 for obesity and holds FDA Breakthrough Therapy designation for metabolic dysfunction-associated steatohepatitis (MASH). Survodutide belongs to the glucagon/GLP-1 "dual agonist" branch of the incretin family — the two-receptor design that sits between single GLP-1 agonists like semaglutide and triple agonists like retatrutide. The glucagon arm is the point of interest: rather than only suppressing appetite and stimulating insulin, glucagon-receptor activation is studied for increasing energy expenditure and, notably, mobilizing fat from the liver. Developed by Boehringer Ingelheim together with Zealand Pharma, it is dosed once weekly and remains investigational. Its most distinctive program is in liver disease: it received FDA Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis) and is in Phase 3 trials there, alongside Phase 3 obesity trials where it has reported double-digit mean weight reductions. It is not FDA-approved. ## Mechanism Dual agonism at the glucagon and GLP-1 receptors — GLP-1 for insulinotropic and satiety effects, glucagon for increased energy expenditure and hepatic-fat reduction. ## Chemistry | Property | Value | | --- | --- | | Molecular formula | C192H289N47O61 | | Molecular weight | 4232 Da | | CAS number | 2805997-46-8 | | PubChem CID | [171378821](https://pubchem.ncbi.nlm.nih.gov/compound/171378821) | ## Research areas Studied in: Obesity, MASH, Type 2 diabetes. Guides on this site: - [Weight Loss & Metabolic Health](https://americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss. ## Key research - Glucagon / GLP-1 dual agonism — pairs GLP-1’s appetite and glycemic effects with glucagon-driven energy expenditure and hepatic-fat mobilization. - MASH — holds FDA Breakthrough Therapy designation for metabolic dysfunction-associated steatohepatitis, its most distinctive Phase 3 program. - Obesity — Phase 3 trials reported substantial double-digit mean weight reduction over ~76 weeks. - Once-weekly — acylated for a long half-life, like the rest of the modern incretin class. - Investigational — developed by Boehringer Ingelheim / Zealand Pharma; not FDA-approved. ## Storage, handling & synthesis **Synthesis.** A ~29-residue glucagon/GLP-1 dual agonist with Aib substitutions and a fatty-acid chain for albumin binding and weekly dosing, built by solid-phase synthesis. The acylation and the sterically hindered Aib couplings are the hard steps, and the length makes deletion-sequence control the dominant purity task. ## FAQs ### What is survodutide? Survodutide (BI 456906) is an investigational once-weekly glucagon / GLP-1 dual receptor agonist from Boehringer Ingelheim, studied for obesity and MASH (fatty liver disease). ### How does it differ from semaglutide or tirzepatide? Semaglutide targets GLP-1 alone and tirzepatide targets GIP + GLP-1; survodutide instead pairs GLP-1 with glucagon-receptor activation, studied for extra energy expenditure and liver-fat reduction. ### What is it studied for in the liver? It has FDA Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis) and is in Phase 3 trials for it — the glucagon arm is of particular interest for hepatic fat. ### Is survodutide approved? No — it is investigational and not FDA-approved. This page is a research and educational reference. ## Latest research Recent trials and publications mentioning Survodutide, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily). ### Recent trials - [LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis](https://clinicaltrials.gov/study/NCT06632457) — RECRUITING · PHASE3 · NCT06632457 - [A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar](https://clinicaltrials.gov/study/NCT07754461) — RECRUITING · PHASE3 · NCT07754461 - [LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis](https://clinicaltrials.gov/study/NCT06632444) — RECRUITING · PHASE3 · NCT06632444 - [A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity](https://clinicaltrials.gov/study/NCT07768813) — NOT_YET_RECRUITING · PHASE1 · NCT07768813 - [A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)](https://clinicaltrials.gov/study/NCT06077864) — COMPLETED · PHASE3 · NCT06077864 - [A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight](https://clinicaltrials.gov/study/NCT06066528) — COMPLETED · PHASE3 · NCT06066528 --- Source: AmericanPeptide.com — https://americanpeptide.com/catalog/survodutide Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com. Research reference only — computational and educational content, not medical advice.